|Articles|April 16, 2021

COVID-19 Updates: US Vaccinations and Global Cases and Deaths as of April 16, 2021

Data from the Johns Hopkins COVID-19 interactive map and the CDC on COVID-19 cases, mortalities, vaccinations, and more.

How many people in the US have been vaccinated against COVID-19?

According to the US Centers for Disease Control and Prevention, as of today, April 16, 2021, at 12:51 PM, EDT:

• 38.5% of total US population have received at least 1 dose
• 24.3% of total US population are fully vaccinated

The 5 states with the highest percentage of population fully vaccinated are:

1. Maine: 31.5%
2. New Mexico: 31.3%
3. Alaska: 31.2%
4. Rhode Island: 30.9%
5. Connecticut: 30.4%

How many cases of COVID-19 have been confirmed in the US?

According to the Johns Hopkins COVID-19 interactive map, as of today, April 16, 2021 at 1:21 PM, EDT, there have been:

• 31 524 464 confirmed cases
• 565 695 deaths

The 5 states with the highest total confirmed cases are:

1. California: 3 712 046
2. Texas: 2 844 303
3. Florida: 2 148 448
4. New York: 1 983 011
5. Illinois: 1 296 269

Deaths: California has the most deaths due to COVID-19 with 60 860 reported fatalities, followed by New York with 51 470, and Texas with 49 443.

How many cases of COVID-19 have been confirmed globally?

Globally, there have been 139 403 270 confirmed cases, 2 991 106 deaths, and 79 445 321 recoveries.

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Related to this article

September 3rd, 2026

FDA Approves Pfizer-BioNTech XFG-Adapted COVID-19 Vaccine for 2026-27 Season

FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.

September 2nd, 2026

Independent Review Supports Respiratory Virus Immunizations for 2026-27 Season

A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.

August 25th, 2026

Pre-Vaccine Antibodies May Predict Blunted COVID-19 Vaccine Response

Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.

October 6th, 2026

9 Drugs Approved for Primary Care: Q3 2026

Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.

August 31st, 2026

FDA Approves Bixlenvo for HIV-1 Switch Therapy in Virologically Suppressed Adults

FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.

August 26th, 2026

FDA Expands Dolutegravir Approval to Infants With HIV-1 Weighing at Least 2 kg

FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.

October 9th, 2026

FDA Approves Once-Monthly Olanzapine Injection for Adults With Schizophrenia

FDA approves olanzapine, a once-monthly subcutaneous injection for adults with schizophrenia, boosting symptom control while reducing monitoring needs and highlighting weight risks.

October 8th, 2026

Abbott Gains FDA Approval for CardioMEMS Update Letting Heart Failure Patients View Pressure Readings on Their Phones

The CardioGuide HF app from Abbott will show patients their pulmonary artery pressure trends and deliver medication instructions set by their care teams.